Miragen Therapeutics, Inc. MGEN, a development-stage biotech company, has product candidates for hematologic cancers and fibrotic diseases in its pipeline. The Analyst Oppenheimer analyst Leah Rush Cann initiated coverage of Miragen with an Outperform and a 12-18-month price target of $13. Read moreSideways will likely continue. $MGEN, Miragen Therapeutics, Inc. / D